CCM
IOBT

CAAS Capital Management’s IO Biotech IOBT Stock Holding History

CAAS Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,479
Closed -$323K – 791
2021
Q4 		$323K Buy
+50,479
New +$488K 0.01% 612

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's IOBT Position: Q1 2022 in Review

CAAS Capital Management sold out of IO Biotech (IOBT) in Q1 2022, closing a stake of 50,479 shares — an estimated $323K sold.

CAAS Capital Management first reported a position in IOBT in Q4 2021 and held it in 1 quarter. The position peaked at $323K in Q4 2021. 19 funds tracked by Wall St. Rank hold IOBT as of Q1 2022.

  • CAAS Capital Management reported no remaining IO Biotech position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 50,479 IO Biotech shares in Q1 2022, an estimated $323K.
  • CAAS Capital Management first reported a position in IO Biotech in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's IO Biotech position peaked at $323K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held IO Biotech as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.